ABIONYX Pharma SA (0RAG.L)
| Previous close | 1.0931 |
| Open | 0.0000 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | 850 |
| Market cap | 229,307 |
| Beta (5Y monthly) | -0.13 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1480 |
| Earnings date | 11 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
PARIS, May 07, 2024--Regulatory News: ABIONYX Pharma (Paris:ABNX):
Business WireABIONYX Pharma: Availability of the Universal Registration Document for the Year 2023
TOULOUSE, France & LAKELAND, Mich., May 02, 2024--Regulatory News: ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces that it has filed with the "Autorité des Marchés Financiers" (AMF) its Universal Registration Document for the year ended December 31, 2023, dated April 30, 2024.
Business WireABIONYX Pharma - Bpifrance Supports the Development of CER-001 in Ophthalmology With a Nearly €1 Million Non-dilutive Innovation Grant
TOULOUSE, France & LAKELAND, Mich., March 14, 2024--Regulatory News: ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible) (Paris:ABNX), a new generation biotech company dedicated to the discovery and development of innovative therapies based on the world’s only natural recombinant apoA-I, announces a nearly €1 million innovation grant from Bpifrance. The aim of this grant is to support the development of drug candidate CER-001 in the treatment of a severe indication in ophthalmology.
